Page:Interim Staff Report on Investigation into Risky MPXV Experiment at the National Institute of Allergy and Infectious Diseases.pdf/23

 : ''With respect to review for DURC, there was no indication from the documents that the IBC reviewed for DURC or referred for DURC review in 2015 and 2018. According to a 2023 PNAS article by the Moss team about other research on MPXV, all procedures and protocols were approved by the NIH IBC and judged not to have the potential for DURC. This suggests that there was DURC review for MPXV experiments, but there has not yet been any evidence showing that the MPXV gene transfer experiments were reviewed for DURC.''

 May 30, 2023, Committee Letter 

On May 30, 2023, Chair Rodgers, Health Subcommittee Chair Guthrie, and O&I Subcommittee Chair Griffith sent a letter to the HHS Assistant Secretary for Legislation as a follow up to HHS’s April 26, 2023, letter, which did not respond directly to most of the questions in the Committee’s March 2023 letter. Because HHS had not been forthcoming with documents and written responses, the Committee requested a videotaped, transcribed in-person interview with Dr. Moss by June 30, 2023.

 June 22, 2023, STAT Article 

In a June 22, 2023, STAT article, NIAID denied Dr. Moss had made any formal proposal for the MPXV experiment:

But a spokesperson for NIAID told STAT in late May that there had been no formal proposal from Moss to do the research